dimethyl sulfoxide has been researched along with Bladder Cancer in 18 studies
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.
dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human urinary bladder cancer is the fifth most common cancer, with a worldwide estimate of about two million patients." | 1.40 | Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. ( Cho, BW; Choi, YH; Darvin, P; Joung, YH; Kang, DY; Kim, HS; Kim, SY; Lee, HK; Na, YM; Park, JH; Park, KD; Sp, N; Yang, YM; Yoo, YB, 2014) |
| "We report a case of recurrence of multifocal primary amyloidosis of urinary bladder." | 1.35 | Recurrent multifocal primary amyloidosis of urinary bladder. ( Devra, A; Dholakia, M; Dholaria, P; Gupta, B; Patel, S; Shah, SA; Trivedi, A, 2008) |
| "Of 25 bladder cancer patients, 11 received 6 weeks of intravesical Bacille Calmette-Guerin (BCG), and 14 were treated weekly with intravesical dimethylsulfoxide (DMSO) for 4 weeks to further modulate biomarker expression." | 1.30 | Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. ( Bonner, RB; Hemstreet, GP; Hurst, RE; Mellott, JE; Rao, J; Rooker, GM, 1999) |
| "Epirubicin fluorescence was observed in the entire bladder wall of normal or hyperplastic regions in rats that were given DMSO prior to epirubicin." | 1.30 | Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model. ( Göğüş, O; Ozdiler, E; Sözen, S; Yaman, O, 1999) |
| " The extent of benzidine absorption in skin sections dosed with either B + A (0." | 1.29 | In vitro percutaneous absorption of benzidine in complex mechanistically defined chemical mixtures. ( Baynes, RE; Brownie, C; Freeman, H; Riviere, JE, 1996) |
| "Female Wistar rats with bladder tumors underwent intravesical instillation of normal saline (S group) or 50% DMSO (D group) prior to the administration of pirarubicin (tetrahydropyranyl-Adriamycin)." | 1.28 | Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. ( Hashimoto, H; Nishihara, M; Sasaki, M; Tokunaka, S; Yachiku, S, 1992) |
| "Hematoporphyrin derivative is a solution containing a complex mixture of dicarboxylic porphyrins such as hematoporphyrin IX, monohydroxyethyl monovinyl deuteroporphyrin isomers, and protoporphyrin IX in addition to porphyrin aggregates of variable molecular sizes." | 1.27 | Solid-phase purification and analysis of dicarboxylic porphyrins extracted from cultured tumor cells. ( Garbo, GM; Keck, RW; Kramer, JB; Kreimer-Birnbaum, M; Selman, SH, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (33.33) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Joung, YH | 1 |
| Na, YM | 1 |
| Yoo, YB | 1 |
| Darvin, P | 1 |
| Sp, N | 1 |
| Kang, DY | 1 |
| Kim, SY | 1 |
| Kim, HS | 2 |
| Choi, YH | 1 |
| Lee, HK | 1 |
| Park, KD | 1 |
| Cho, BW | 1 |
| Park, JH | 1 |
| Yang, YM | 1 |
| Mevcha, A | 1 |
| Calleary, J | 1 |
| Gillatt, DA | 1 |
| Chen, D | 1 |
| Song, D | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| Patel, S | 1 |
| Trivedi, A | 1 |
| Dholaria, P | 1 |
| Dholakia, M | 1 |
| Devra, A | 1 |
| Gupta, B | 1 |
| Shah, SA | 1 |
| Baynes, RE | 1 |
| Brownie, C | 1 |
| Freeman, H | 1 |
| Riviere, JE | 1 |
| Hemstreet, GP | 2 |
| Rao, J | 2 |
| Hurst, RE | 2 |
| Bonner, RB | 2 |
| Waliszewski, P | 1 |
| Grossman, HB | 1 |
| Liebert, M | 1 |
| Bane, BL | 1 |
| Mellott, JE | 1 |
| Rooker, GM | 1 |
| Yaman, O | 1 |
| Ozdiler, E | 1 |
| Sözen, S | 1 |
| Göğüş, O | 1 |
| Bookland, EA | 1 |
| Reznikoff, CA | 1 |
| Lindstrom, M | 1 |
| Swaminathan, S | 1 |
| Ohtani, M | 1 |
| Miyanaga, N | 1 |
| Noguchi, R | 1 |
| Sasaki, A | 1 |
| Akaza, H | 1 |
| Koiso, K | 1 |
| Tanaka, Y | 1 |
| Tobisu, K | 1 |
| Kakizoe, T | 1 |
| See, WA | 1 |
| Xia, Q | 1 |
| Hashimoto, H | 1 |
| Tokunaka, S | 1 |
| Sasaki, M | 1 |
| Nishihara, M | 1 |
| Yachiku, S | 1 |
| Garbo, GM | 1 |
| Kramer, JB | 1 |
| Keck, RW | 1 |
| Selman, SH | 1 |
| Kreimer-Birnbaum, M | 1 |
| Konowalchuk, TW | 1 |
| Elhilali, M | 1 |
| Mackillop, WJ | 1 |
| Walker, L | 1 |
| Walker, MC | 1 |
| Parris, CN | 1 |
| Masters, JR | 1 |
| Nicolas, J | 1 |
| Vieillefond, A | 1 |
| Benoit, G | 1 |
| Jardin, A | 1 |
| Neveux, Y | 1 |
| Martin, E | 1 |
| Sander, J | 1 |
| Bürkle, G | 1 |
| Bürkle, V | 1 |
| Stewart, BH | 1 |
| Branson, AC | 1 |
| Hewitt, CB | 1 |
| Kiser, WS | 1 |
| Straffon, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Treatment of Refractory Bladder Pain Syndrome With Dimethyl Sulfoxide (DMSO) Alone and DMSO as a Carrier Molecule for Botulinum Toxin A Instillation.[NCT03103594] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dimethyl sulfoxide and Bladder Cancer
| Article | Year |
|---|---|
G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Topics: Actins; Aminobiphenyl Compounds; Anticarcinogenic Agents; BCG Vaccine; Biomarkers, Tumor; Carcinogen | 1996 |
17 other studies available for dimethyl sulfoxide and Bladder Cancer
| Article | Year |
|---|---|
Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.
Topics: Animals; Cell Movement; Cell Survival; Dimethyl Sulfoxide; Gene Expression Regulation, Neoplastic; H | 2014 |
Re: Ocular side-effects of urological pharmacy.
Topics: Antineoplastic Agents; BCG Vaccine; Dimethyl Sulfoxide; Eye Diseases; Humans; Mitomycin; Urinary Bla | 2009 |
Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dimethyl Sulfoxide; Dogs; Dose-Response Relationship, Dr | 2003 |
Recurrent multifocal primary amyloidosis of urinary bladder.
Topics: Adult; Amyloidosis; Colchicine; Dimethyl Sulfoxide; Humans; Male; Recurrence; Urinary Bladder Neopla | 2008 |
In vitro percutaneous absorption of benzidine in complex mechanistically defined chemical mixtures.
Topics: Animals; Benzidines; Dimethyl Sulfoxide; Perfusion; Skin Absorption; Surface-Active Agents; Swine; U | 1996 |
Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide.
Topics: Actins; Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Biomarkers, Tumor; Chemoprevention; Combined M | 1999 |
Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinogens; Dimethyl Sulfoxide; | 1999 |
Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxy derivatives.
Topics: Aminobiphenyl Compounds; Cell Line, Transformed; Dimethyl Sulfoxide; Drug Resistance; Humans; Hypoxa | 1992 |
[Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice].
Topics: Administration, Intravesical; Animals; Butylhydroxybutylnitrosamine; Dimethyl Sulfoxide; Female; Mic | 1992 |
Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Dimethyl Sulfoxide; Doxorubicin | 1992 |
Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder.
Topics: Absorption; Animals; Dimethyl Sulfoxide; Doxorubicin; Female; Microscopy, Fluorescence; Rats; Rats, | 1992 |
Solid-phase purification and analysis of dicarboxylic porphyrins extracted from cultured tumor cells.
Topics: Animals; Carcinoma, Transitional Cell; Cells, Cultured; Chromatography, DEAE-Cellulose; Chromatograp | 1985 |
In vitro drug sensitivity studies in human transitional cell carcinoma of the bladder.
Topics: Carcinoma, Transitional Cell; Clone Cells; Colony-Forming Units Assay; Culture Techniques; Dimethyl | 1987 |
Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1988 |
[The value of measuring membrane potentials of urothelial cells using cytofluorometry in the study of tumors of the bladder. Preliminary analysis].
Topics: Biomarkers, Tumor; Carbocyanines; Dimethyl Sulfoxide; Epithelium; Flow Cytometry; Fluorescent Dyes; | 1988 |
[Induction of lungtumors and tumors of the urinary bladder in rats by di-n-butyl nitrosamine in dimethyl sulfoxide].
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Dimethyl Sulfoxide; Drug Interactions; Injections | 1974 |
The treatment of patients with interstitial cystitis, with special reference to intravesical DMSO.
Topics: Animals; Cataract; Cystitis; Dimethyl Sulfoxide; Dogs; Eye; Female; Humans; Male; Ophthalmoscopy; Ti | 1971 |